MedinCell S.A. (MEDCL.PA)

6.3 €

+0.14 (+2.27%)
Rating:
Recommendation:
-
Symbol MEDCL.PA
Price 6.3 €
Beta 0.916
Volume Avg. 0.03M
Market Cap 158.130M
Shares () -
52 Week Range 4.73-10.74
1y Target Est -
DCF Unlevered MEDCL.PA DCF ->
DCF Levered MEDCL.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity -431.34% Strong Sell
P/E -7.48 Strong Sell
P/B -11.72 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Christophe Douat
Healthcare
Biotechnology
Paris

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.